ImmunoGen, Inc.

Licenses tumor-activated prodrug technology, for development of small molecule anticancer agents, to optimise potency and toxicity. Manufacturing in Norwood, and headquarters in Cambridge, Massachusetts. (Nasdaq: IMGN)